# Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

> **NCT02883062** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 67 (actual)

## Conditions studied

- Invasive Breast Carcinoma
- Stage II Breast Cancer AJCC v6 and v7
- Stage III Breast Cancer AJCC v7
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **PROCEDURE:** Lumpectomy
- **PROCEDURE:** Mastectomy
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02883062
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-02
- **Primary completion:** 2019-12-18
- **Final completion:** 2026-09-11
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02883062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02883062, "Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02883062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*